SEARCH

SEARCH BY CITATION

References

  • Altman, D.G. & Bland, J.M. (1995) Absence of evidence is not evidence of absence. British Medical Journal, 311, 485.
  • Assmann, S.F., Pocock, S.J., Enos, L.E. & Kasten, L.E. (2000) Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet, 355, 106469.
  • Berry, B.G. (2006) Bayesian clinical trials. Nature Reviews Drug Discovery, 5, 2736.
  • Burnett, A.K., Grimwade, D., Solomon, E., Wheatley, K. & Goldstone, A.H. on bhelaf of the MRC Adult Leukaemia Working Party (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood, 93, 41314143.
  • Burnett, A.K., Milligan, D., Prentice, A.G., Goldstone, A.H., McMullin, M.F., Hills, R.K. & Wheatley, K. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109, 11141124.
  • Burnett, A.K., Milligan, D., Goldstone, A., Prentice, A., McMullin, M.F., Dennis, M., Sellwood, E., Pallis, M., Russell, N., Hills, R.K. & Wheatley, K. United Kingdom National Cancer Research Institute Haematological Oncology Study Group (2009) The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology, 145, 318332.
  • Burnett, A., Hills, R., Hunter, A.E., Milligan, D., Kell, W.J., Wheatley, K., Yin, J., McMullin, M.F., Dignum, H., Bowen, D. & Russell, N.H. (2010a) The addition of gemtuzumab ozogamicin to low dose Ara-C improves remission rates but not survival: results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” comparison. Blood, 116, 1314.
  • Burnett, A.K., Hills, R.K., Milligan, D.W., Goldstone, A.H., Prentice, A.G., McMullin, M.F., Duncombe, A., Gibson, B. & Wheatley, K. (2010b) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of Clinical Oncology, 28, 586595.
  • Burnett, A.K., Hills, R.K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N.H., Yin, J.A., Hunter, A., Goldstone, A.H. & Wheatley, K. (2011a) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Journal of Clinical Oncology, 29, 369377.
  • Burnett, A.K., Hills, R.K., Hunter, A.E., Milligan, D.W., Kell, W.J., Wheatley, K., Yin, J.L., Ali, S., Kjeldsen, L., Bowen, D. & Russell, N.H. (2011b) The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Blood (ASH Annual Meeting Abstracts), 118, Abstract 582.
  • Burnett, A.K., Goldstone, A.H., Hills, R.K., Milligan, D., Prentice, A., Yin, J., Wheatley, K., Hunter, A. & Russell, N.H. (2012) The curability of patients with AML who were not transplanted in first remission. Journal of Clinical Oncology, (in press).
  • Cameron, D., Cooper, M., Haward, R., Kaplan, R., Poole, K., Lester, N., McLaren, R., Moser, R., Parmar, M., Moser, R., Stead, M. & Selby, P. (2010) Four-fold increase in recruitment of cancer patients to NCRN portfolio studies between 2001 and 2010: a tale of investment bringing returns. Proceeding of the National Cancer Research Institute Cancer Conference, 2010. Abstract C64. http://www.ncri.org.uk/ncriconference/2010abstracts/abstracts/C64.htm.
  • Castaigne, S., Pautas, C., Terre, C., Raffoux, E., Bordessoule, D, Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., de Revel, T., Gastaud, L., Gardin, C., Sutton, L., Marroleau, J.P., de Botton, S., Hermine, O., Plantier, I., Janvier, M., Dupriez, B., Simon, M., de Gunzburg, N., Foucault-Haiat, S., Contentin, N., Berthon, C., Fenaux, P., Henry, E., Rousselot, P., Preudhomme, C., Chevret, S. & Dombret, H. (2011) Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AML patients aged 50–70 years old: a prospective randomized phase 3 trial from the acute leukemia french association (ALFA). Blood (ASH Annual Meeting Abstracts), 118, Abstract 6.
  • Christie, D.A. & Tansey, E.M. (ed.) (2003) Leukaemia: Wellcome Witnesses to Twentieth Century Medicine, vol 15. Wellcome Trust Centre for the History of Medicine at UCL, London.
  • Clarke, M. & Halsey, J.M. (2001) DICE 2: a further investigation of the effects of chance in life, death and subgroup analyses. International Journal of Clinical Practice, 55, 240242.
  • Collins, R., Peto, R., Gray, R. & Parish, S. (1996) Large-scale randomized evidence: trials and overviews. In: Oxford Textbook of Medicine (ed. by D. Weatherall, J.G.G. Ledingham & D.A. Warrell), pp. 2136. Oxford University Press, Oxford.
  • Doll, R. (1991) Darwin Lecture. development of controlled trials in preventive and therapeutic medicine. Journal of Biosocial ScienceI, 23, 36578.
  • Doll, R. (1992) Sir Austin Bradford Hill and the progress of medical science. British Medical Journal, 305, 15216.
  • Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W.N., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Laurie Letvak, L. & Larson, R.A. for the IRIS Investigators (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355, 240817.
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (1990) Treatment of Early Breast Cancer. Volume 1: Worldwide Evidence 1985–1990. Oxford University Press, Oxford.
  • Eden, O.B., Harrison, G., Richards, S., Lilleyman, S., Bailey, C.C., Chessells, J.M., Hann, I.M., Hill, F.G.H. & Gibson, B.E.S. (2000) Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980–1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia, 14, 23072320.
  • Fisher, R.A. (1926) The arrangement of field experiments. Journal of the Ministry of Agriculture of Great Britain, 33, 503513.
  • Gardner, M.J. & Altman, D.G. (1996) Confidence intervals rather than P values: estimation rather than hypothesis testing. British Medical Journal, 292, 74650.
  • Gray, R. & Wheatley, K. (1991) How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplantation, 7(Suppl. 3), 912.
  • Hill, A.B. (1937) Principles of Medical Statistics. Lancet, London.
  • Hill, A.B. (1951) The clinical trial. British Medical Bulletin, 7, 278282.
  • Hill, A.B. (1966) Reflections on the controlled trial. (Heberden Oration, 1965). Annals of the Rheumatic Diseases, 25, 107113.
  • Hill, A.B. (1990) Memories of the British streptomycin trial in tuberculosis: the first randomised controlled trial. Controlled Clinical Trials, 11, 7779.
  • Hills, R.K. & Burnett, A.K. (2011) Applicability of a “Pick a Winner” trial design to acute myeloid leukemia. Blood, 118, 23892394.
  • Hills, R.K., Richards, S.M. & Wheatley, K. (2003) Corner cutting compromises clinical trials: the inherent problems with up-front randomisation and a common standard arm. Leukemia Research, 27, 10711073.
  • Hills, R.K., Gray, R. & Wheatley, K. (2007) Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction. Journal Of Evidence Based Medicine, 2, 196204.
  • Lewis, J.A. & Machin, D. (1993) Intention to treat – who should use ITT? British Journal of Cancer, 68, 647650.
  • Lionberger, J.M., Dorcy, K.S., Dean, C., Holm, N., Scott, B.L., Wathen, J.K., Estey, E.H. & Pagel, J.M. (2011) Innovative phase I/II statistical design in combination chemotherapy that combines toxicity and efficacy parameters to increase study efficiency: bendamustine and idarubicin in de novo adult AML. Blood (ASH Annual Meeting Abstracts), 118, Abstract 1552.
  • Lo-Coco, F., Avvisati, G., Vignetti, M., Fioritoni, G., Liso, V., Ferrara, F., Cimino, G., Gallo, E., Rossi, G., Giustolisi, R., Rodeghiero, F., Nicola Cantore, N., Tiziano Barbui, T., Paola Fazi, P., Antonio Peta, A., Alberto Bosi, A., Enrico Madon, E., Andrea Biondi, A., Giuseppe Masera, G., Francesco Nobile, F., Salvatore Mirto, S., Maria, C., Petti, M.C. & Mandelli, F. (2004) Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA group. Blood (ASH Annual Meeting Abstracts), 104, Abstract 392.
  • Machin, D., Campbell, M.J., Tan, S.B. & Tan, S.H. (2009) Sample Size Tables for Clinical Studies, 3rd edn. Wiley–Blackwell, Oxford.
  • Mauri, L. (2012) Why we still need randomized trials to compare effectiveness. New England Journal of Medicine, 366, 153840.
  • Wheatley, K. (2002) SAB – a promising new treatment to improve remission rates in AML in the elderly? British Journal of Haematology, 118, 432433.